Table 1.
Characteristics of the SMARTT Study Population of HIV-Exposed but Uninfected Infants by Year of Birth (n=1768)
| |
|
Year of birth |
|||
|---|---|---|---|---|---|
| Characteristic | Total (n=1768) | 1995–1997 (n=67) | 1998–2002 (n=399) | 2003–2006 (n=487) | 2007–2009 (n=815) |
| Gender | |||||
| Male | 905 (51%) | 31 (46%) | 211 (53%) | 253 (52%) | 410 (50%) |
| Female | 863 (49%) | 36 (54%) | 188 (47%) | 234 (48%) | 405 (50%) |
| Race | |||||
| Black or African American | 1117 (63%) | 44 (66%) | 262 (66%) | 281 (58%) | 530 (65%) |
| White | 496 (28%) | 19 (28%) | 93 (23%) | 158 (32%) | 226 (28%) |
| Other/more than one race/unknown | 155 (9%) | 4 (6%) | 44 (11%) | 48 (10%) | 59 (7%) |
| Ethnicity | |||||
| Hispanic or Latino | 587 (33%) | 15 (22%) | 126 (32%) | 193 (40%) | 253 (31%) |
| Not Hispanic or Latino | 1168 (66%) | 52 (78%) | 272 (68%) | 290 (60%) | 554 (68%) |
| More than one ethnicity/unknown | 13 (1%) | 0 (0%) | 1 (0%) | 4 (1%) | 8 (1%) |
| First maternal viral load during pregnancy (copies/mL) | |||||
| None | 137 (8%) | 43 (64%) | 52 (13%) | 28 (6%) | 14 (2%) |
| <1000 | 673 (38%) | 5 (7%) | 125 (31%) | 197 (40%) | 346 (42%) |
| 1000–9999 | 444 (25%) | 6 (9%) | 105 (26%) | 128 (26%) | 205 (25%) |
| 10,000–100,000 | 391 (22%) | 11 (16%) | 80 (20%) | 108 (22%) | 192 (24%) |
| ≥100,000 | 98 (6%) | 0 (0%) | 26 (7%) | 23 (5%) | 49 (6%) |
| Unknown | 25 (1%) | 2 (3%) | 11 (3%) | 3 (1%) | 9 (1%) |
| Last maternal viral load during pregnancy (copies/mL) | |||||
| None | 137 (8%) | 43 (64%) | 52 (13%) | 28 (6%) | 14 (2%) |
| <1000 | 1301 (74%) | 8 (12%) | 245 (61%) | 380 (78%) | 668 (82%) |
| 1000–9999 | 176 (10%) | 4 (6%) | 46 (12%) | 51 (10%) | 75 (9%) |
| 10,000–100,000 | 88 (5%) | 7 (10%) | 34 (9%) | 17 (3%) | 30 (4%) |
| ≥100,000 | 10 (1%) | 0 (0%) | 2 (1%) | 4 (1%) | 4 (0%) |
| Unknown | 56 (3%) | 5 (7%) | 20 (5%) | 7 (1%) | 24 (3%) |
| First maternal CD4 count during pregnancy (cells/mm3) | |||||
| None | 226 (13%) | 6 (9%) | 48 (12%) | 61 (13%) | 111 (14%) |
| 0–199 | 397 (22%) | 16 (24%) | 78 (20%) | 103 (21%) | 200 (25%) |
| 200–349 | 404 (23%) | 17 (25%) | 90 (23%) | 101 (21%) | 196 (24%) |
| 350–499 | 614 (35%) | 16 (24%) | 127 (32%) | 187 (38%) | 284 (35%) |
| ≥500 | 102 (6%) | 10 (15%) | 45 (11%) | 32 (7%) | 15 (2%) |
| Unknown | 25 (1%) | 2 (3%) | 11 (3%) | 3 (1%) | 9 (1%) |
| Trimester of first maternal viral load or CD4 measurement during pregnancy | |||||
| No measurement | 82 (5%) | 9 (13%) | 38 (10%) | 24 (5%) | 11 (1%) |
| Trimester 1 | 912 (52%) | 18 (27%) | 162 (41%) | 298 (61%) | 434 (53%) |
| Trimester 2 | 609 (34%) | 27 (40%) | 145 (36%) | 126 (26%) | 311 (38%) |
| Trimester 3 | 138 (8%) | 11 (16%) | 41 (10%) | 36 (7%) | 50 (6%) |
| Unknown | 27 (2%) | 2 (3%) | 13 (3%) | 3 (1%) | 9 (1%) |
| Maternal substance use during pregnancy | |||||
| Tobacco | 296 (17%) | 8 (12%) | 69 (17%) | 84 (17%) | 135 (17%) |
| Alcohol | 130 (7%) | 1 (1%) | 26 (7%) | 26 (5%) | 77 (9%) |
| Marijuana | 99 (6%) | 1 (1%) | 18 (5%) | 30 (6%) | 50 (6%) |
| Other substances | 156 (9%) | 4 (6%) | 27 (7%) | 45 (9%) | 80 (10%) |
| Unknown | 159 (9%) | 13 (19%) | 65 (16%) | 48 (10%) | 33 (4%) |
SMARTT, Surveillance Monitoring for ART Toxicities.